with approximately 300 million chronic carriers and the development of severe complications such as liver cirrhosis and hepatocellular carcinoma [1] . The course of HBV infection depends on several factors modifying the immune response, including age at infection and host genetic factors [2] , and it probably also depends on the genetic variability of the virus, which influences the expression of viral antigens. Indeed, HBV replicates via a reversetranscription step and is estimated to have a high mutation rate [3] . On the basis of a comparison of complete genomic sequences, seven major viral genotypes, designated A to G, have been identified and correspond to viral isolates sharing more than 80% homology in their nucleotide sequences [4] [5] [6] [7] . HBV genotypes have distinct geographical distributions.
Genotype A is found in North America [4] and Northern Europe, as well as in parts of Africa [8, 9] , while genotypes B and C are the most common in Southeast Asia [4] . Genotype D is found universally [8] . Genotype E is predominantly found in Africa [8] , and F clusters in Central and South America [10] . Genotype G has been reported in the United States and France [7] .
Accumulating evidence suggests that HBV genotypes have an impact on the pattern of mutations in the pre-core (PC) and core promoter (CP) regions, the natural course of chronic HBV infection [11] [12] [13] [14] [15] , or the severity of underlying liver disease [16, 17] . Genotypes B and C have been studied most extensively due to their co-circulation in Asia, eliminating differences in ethnic or racial background of the patients. These studies have shown that genotype B, compared to genotype C, is associated with a higher rate of seroconversion from HBeAg to anti-HBe antibody, less active liver disease, and a lower rate of progression to cirrhosis.
Correspondingly, genotype C is more prevalent among HBeAg-positive patients than genotype B. Similarly, compared to genotype D, genotype A is more prevalent in HBeAgpositive than in anti-HBe-positive antibody patients. Several studies indicate that HBV genotypes may be associated with differences in treatment response [18] [19] [20] . Genotype C is associated with a lower response rate to alpha interferon therapy compared to genotype B. In Caucasian patients, a better response to peginterferon alpha-2b and lamivudine was found when patients were infected with genotype A vs genotype D. Investigating the clinical significance of HBV genotypes is becoming increasingly relevant. The identification of HBV genotypes could be useful to monitor HBV infection and related diseases and may also help in implementing appropriate therapeutic regimens.
To date, there are little data on the prevalence and clinical significance of HBV genotypes in France. One previous study suggested that HBV genotypes A and D were predominant in this country and that genotype A was associated with HBeAg positivity, while genotype D was associated with HBeAg negativity [21] . Another study by Ganne-Carrié et al. concluded that HBV genotypes A, B, C, D, and E circulated in the Seine Saint Denis District, close to Paris, reflecting the multiple geographical origins of patients [22] .
The aim of this study was to determine the prevalence and the distribution of HBV genotypes among a consecutive sample of patients with HBV infection with or without HIV coinfection in Bordeaux hospital (France) that caters to patients from various parts of Southwestern France. Additional objectives were to determine whether there was an association of HBV genotypes with patients demographics, clinical status, and PC and CP variants. The amplified PCR products were purified by the QIA quick PCR purification kit (Qiagen) and then used for direct sequencing using internal antisense primer. Sequencing of the purified products was conducted on a CEQ automatic sequencer (Beckman Coulter, Fullerton, CA) with the CEQ DTCS Quick Start kit (Beckman Coulter). Analysis of each sequence was conducted using Seq Analysis and Seq Investigator software (Beckman Coulter).
MATERIALS AND METHODS

Patients
For genotype characterization, all sequences obtained were compared to at least 24 Genbank sequences representative of all known HBV genotypes.
Statistical analysis. HIV coinfection was present in 57/159 (36%) patients screened. Eighty-two patients (42.3%)
were HBeAg-positive and 52 (26.8%) were currently receiving anti-HBV treatment (interferon: 9 patients, pegylated interferon: 3, lamivudine: 31, adefovir: 2, lamivudine and tenofovir: 7).
Seven HBV genotypes were found in the studied population. Genotypes A and D were the most common. Genotypes G and F were present in only 2.6% of the study population (Table   2) .
No association was found between median age and HBV genotypes (p = 0.28). There was a strong association between ethnicity and HBV genotypes (P<0.001 for the overall comparison). Genotype A was almost exclusively carried by Caucasian patients (96%), africans were most frequent among genotype E (82%), and asians were most prevalent among genotypes B and C (82% and 80%, respectively). The presumed mode of infection was known in 80 patients (41%). Of these, 58% were presumed to have acquired HBV infection through sexual intercourse and 20% through intravenous drug use (Table 1 ). There was a strong association between the presumed mode of infection and HBV genotypes (P=0.01 overall). Among genotype A, patients infected via sexual route were predominant, whereas among genotype D, patients infected via drug use were most prevalent (Table 2 ).
There was a strong association between HIV status and HBV genotypes (P<0.001). HIV coinfection was common in patients with genotypes A and D (45.3% and 34.2%, respectively) and absent in patients with genotypes B and C ( Table   2 ).
The proportion of patients with increased ALT over the upper limit of normal was not significantly different between HBV genotypes (p = 0.4). No association was found between liver activity and HBV genotypes (p = 0.47). On the other hand, there was an association between liver fibrosis and HBV genotypes (p = 0.01). The prevalence of severe liver fibrosis (F3 or F4 METAVIR score) was higher in HBV genotypes A and E-infected patients (Table   2 ).
HBV genotypes, HBeAg status and PC/CP variants.
Genotypes A and C were associated with a higher prevalence of HBeAg (53% and 55%, respectively) ( Table 2) . A strong correlation was found between HBV genotypes and PC as well as CP variants (Table 2 and Figure 1 was discovered in 2000 [7] , epidemiological data are limited. HBV genotype G has been reported in France, Georgia, Germany, and Mexico, but not in Japan [7, [26] [27] [28] .
We found a strong correlation between HBV genotypes and the presumed mode of infection, but the latter may merely be a surrogate marker of ethnicity or place of birth. However, These studies showed that genotype C was associated with higher virus loads [29] and more aggressive liver disease [17, 30] . On the other hand there is a dearth of studies comparing genotypes A and D. In India, genotype D is reported to be associated with more severe liver disease than that associated with genotype A. In contrast, in our study, genotype A was associated with METAVIR fibrosis score F2-F4 in univariate analysis. This result was not confirmed in multivariate analysis. Maybe it is linked to the high prevalence of HIV seropositivity in this group (many studies having shown HIV coinfection as a factor in HBV disease progression), or to the high proportion of patients over 40 yrs. However we cannot exclude a pejorative specific evolution linked to genotype A.
In keeping with the results from other investigators, genotype A and C were associated with a higher prevalence of HBeAg compared with genotypes B and D [12, [31] [32] [33] . Several studies reported a correlation between HBV genotype and HBeAg clearance. These studies found that the prevalence of HBeAg was higher in patients with genotype C compared to those with genotype B suggesting that HBeAg clearance occurred at higher rates among patients with genotype B [13, 16] . Unfortunately, the cross-sectional design of our survey could not address the issue of the association of HBV genotypes with HBeAg seroconversion that has been recently suggested [14, 16] . In multivariate analysis, HBeAg positivity was not an independent factor associated with genotype A. The PC/CP status could probably explain the difference between genotypes A and D concerning HBeAg positivity or negativity more than HBeAg clearance.
Our results clearly show in agreement with others [34] that HBeAg-negative chronic hepatitis is now the predominant form of chronic hepatitis B. In our population the overall proportion of HBeAg-negative chronic hepatitis B was 58%, lower than in a recent study [34] . This difference could be explained by a higher proportion of genotype A in our population, since genotype A is associated with a higher prevalence of HBeAg. Unfortunately, HBV genotyping was not performed by Zarski et al.
We found that PC and CP variants were detected in a substantial proportion (35% and 43%, respectively) of our patients. In patients with chronic HBV infection, HBeAg negative disease is becoming the predominant form of infection and has therapeutic implications [35, 36] . In accordance with previous reports [12, 13, 16, 38] , we found that PC variant (G1896A) was most common in patients with genotype D and rare in patients with genotype A. In our survey, CP variants (A1762T, G1764A) were evenly distributed among HBV genotypes A, C, D and E and relatively rare among HBV genotype B. The association between HBV genotypes and PC (G1896A) variant is related to base pairing in the stem-loop structure of the pregenome encapsidation sequence [11, 12, 38, 39] but its basis has not been deciphered.
Our study showed that PC variants were predominantly detected in HBeAg-negative patients, whereas CP variants were found in both HBeAg-negative and HBeAg-positive patients, as described by others [40, 41] . A more marked increase in the prevalence of PC versus CP variants in HBeAg-negative patients is attributed to the fact that PC (G1896A) variants abolish whereas CP variants (A1762T, G1764A) only down-regulate HBeAg production.
This study has identified three independent factors associated with genotype A in HBV infected patients: age > 40 yrs, HIV positive status, and absence of PC variant. The proportion of patients with age > 40 yrs was significantly higher, a finding consistent with the recent results of a survey performed in France by Ganne-Carrié et al [22] in which the mean age of patients infected by HBV genotypes B, C, and E, was significantly lower than HBV/A and /D.
In keeping with the results from three recent studies [42] [43] [44] 
